Figure 2: Cellular uptake of CaP-rHDL in an active and cell type-specific manner.

(a) Cellular uptake of DiI-labelled CaP-LNC (DiI-CaP-LNC) and CaP-rHDL (DiI-CaP-rHDL) after incubation for 3 h at the DMPC concentration ranged from 1 to 20 μg ml⁻¹ in C6 glioblastoma cells at 37 °C. Red: DiI-labelled nanoparticles. Blue: nuclei. Scale bar, 200 μm. (b) Quantitative cellular uptake of DiI-CaP-LNC and DiI-CaP-rHDL in C6 glioblastoma cells at 4 °C and 37 °C, respectively, after incubation for 3 h at the nanoparticle concentrations from 1 to 20 μg ml⁻¹. (c) Cellular uptake of DiI-CaP-LNC and DiI-CaP-rHDL in C6 glioblastoma cells after different incubation time ranged from 0.2 to 6 h at the nanoparticles concentration of 5 μg ml⁻¹ at 37 °C. For b and c, data represent mean±s.d. (n=3). ***P<0.001 significantly higher than the cellular uptake of CaP-LNC at 37 °C. The significance of the differences was evaluated by two-tailed Student’s t-test. (d) Cellular uptake of DiI-CaP-rHDL in C6 glioblastoma cells and primary astrocytes after incubation for 1.5 h at the nanoparticles concentration of 5 μg ml⁻¹. Scale bar, 50 μm. Data represent mean±s.d. (n=3). The significance of the differences (***P<0.001) was evaluated by two-tailed Student’s t-test.